NASDAQ:IMNM Immunome Q4 2025 Earnings Report $25.75 +0.68 (+2.71%) Closing price 04:00 PM EasternExtended Trading$25.87 +0.12 (+0.47%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunome EPS ResultsActual EPS-$0.75Consensus EPS -$0.65Beat/MissMissed by -$0.10One Year Ago EPSN/AImmunome Revenue ResultsActual RevenueN/AExpected Revenue$0.79 millionBeat/MissN/AYoY Revenue GrowthN/AImmunome Announcement DetailsQuarterQ4 2025Date3/3/2026TimeBefore Market OpensConference Call DateTuesday, March 3, 2026Conference Call Time3:00PM ETUpcoming EarningsImmunome's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Immunome Earnings HeadlinesImmunome (NASDAQ:IMNM) Coverage Initiated at Alliance Global PartnersSeptember 21 at 9:06 AM | americanbankingnews.comImmunome, Inc. (NASDAQ:IMNM) Receives $34.64 Consensus Target Price from AnalystsSeptember 17, 2026 | americanbankingnews.com“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown, founder of Brownstone Research, calls it M.A.G.I. Venture capitalist Jason Calacanis, who turned $100,000 into $100 million from Uber's IPO, previewed the technology privately and called it the best selling product he has ever seen.September 22 at 1:00 AM | Brownstone Research (Ad)Immunome (NASDAQ:IMNM) Earns Buy Rating from HC WainwrightSeptember 12, 2026 | americanbankingnews.comImmunome, Inc. (IMNM) Latest Press Releases & Corporate News - Yahoo FinanceSeptember 9, 2026 | finance.yahoo.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 8, 2026 | businesswire.comSee More Immunome Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email. Email Address About ImmunomeImmunome (NASDAQ:IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development. Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases. Its pipeline and product candidates are subject to ongoing preclinical and clinical evaluation, and the company may collaborate with pharmaceutical and biotechnology partners to advance selected programs. Historically, Immunome applied its human antibody discovery platform to infectious-disease research, including the identification of antibodies against COVID-19. The company has since expanded its focus toward broader therapeutic applications, particularly cancer and immune-related conditions. Immunome is based in the United States and serves global pharmaceutical and healthcare markets through research, development and potential commercialization of its therapies.View Immunome ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s Muse Highlights Arm’s Growing Role in AI InfrastructureNucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
